The litigation centers on disclosures made on May 4, 2026, when GeneDx reported a decline in adjusted gross margins from 74% to 69%. The company missed revenue targets for its exome and genome product lines, subsequently slashing its full-year revenue guidance to a range of $475 million to $490 million, down from an earlier projection of $540 million to $550 million.

Central to the complaint is a $31.2 million impairment loss tied to the acquisition of Fabric Genomics. While GeneDx previously marketed the AI-driven firm as a transformative engine for recurring revenue, the market reaction to these combined financial setbacks was severe, triggering a 49.2% drop in share price—a decline of $33.42 per share. ClaimsFiler is currently coordinating legal outreach for affected shareholders through the firm Kahn Swick & Foti, LLC.